Liguang Lou

Liguang Lou

Auto-generated profile, based on publicly available information

Liguang Lou

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2011 in Cancer Science
Verified
Journal Article
Closed access
PDF file
STShu Tian
Shu Tian
HQHaitian Quan
Haitian Quan
CXChengying Xie
Chengying Xie
HGHaiyi Guo
Haiyi Guo
FLFangfang Lü
Fangfang Lü
LLLiguang Lou
Liguang Lou

15 February 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
CXChengying Xie
Chengying Xie
XWXiaozhe Wan
Xiaozhe Wan
HQHaitian Quan
Haitian Quan
MZMingyue Zheng
Mingyue Zheng
LFLi Fu
Li Fu
LLLiguang Lou
Liguang Lou
Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor‐2 (VEGFR2) has been established as a therapeutic strategy for treating cancer. However, because of their low selectivity, most small molecule inhibitors of VEGFR2 tyrosine kinase show unexpected adverse effects and limited anticancer efficacy. In the present study, we detailed the pharmacological properties of anlotinib, a highly potent and selective VEGFR2 inhibitor, in preclinical models. Anlotinib occupied the ATP‐binding pocket of VEGFR2 tyrosine kinase and showed high selectivity and inhibitory potency (IC50 <1 nmol/L) for VEGFR2 relative to other tyrosine kinases. Concordant with this activity, anlotinib inhibited VEGF‐induced signaling and cell proliferation in HUVEC with picomolar IC50 values. However, micromolar concentrations of anlotinib were required to inhibit tumor cell proliferation directly in vitro. Anlotinib significantly inhibited HUVEC migration and tube formation; it also inhibited microvessel growth from explants of rat aorta in vitro and decreased vascular density in tumor tissue in vivo. Compared with the well‐known tyrosine kinase inhibitor sunitinib, once‐daily oral dose of anlotinib showed broader and stronger in vivo antitumor efficacy and, in some models, caused tumor regression in nude mice. Collectively, these results indicate that anlotinib is a well‐tolerated, orally active VEGFR2 inhibitor that targets angiogenesis in tumor growth, and support ongoing clinical evaluation of anlotinib for a variety of malignancies.

1 December 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
XLXin Li
Xin Li
CYChangyong Yang
Changyong Yang
HWHong Wan
Hong Wan
GZGe Zhang
Ge Zhang
JFJun Feng
Jun Feng
LZLianshan Zhang
Lianshan Zhang

21 January 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
LWLei Wang
Lei Wang
CYChangyong Yang
Changyong Yang
CXChengying Xie
Chengying Xie
JJJiahua Jiang
Jiahua Jiang
MGMingzhao Gao
Mingzhao Gao
LLLiguang Lou
Liguang Lou
Poly(ADP‐ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first‐in‐class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA‐mutated ovarian or breast cancer. However, the undesirable hematological toxicity and pharmacokinetic properties of olaparib limit its clinical application. Here, we report the first preclinical characterization of fluzoparib (code name: SHR‐3162), a novel, potent, and orally available inhibitor of PARP. Fluzoparib potently inhibited PARP1 enzyme activity and induced DNA double‐strand breaks, G2/M arrest, and apoptosis in homologous recombination repair (HR)‐deficient cells. Fluzoparib preferentially inhibited the proliferation of HR‐deficient cells and sensitized both HR‐deficient and HR‐proficient cells to cytotoxic drugs. Notably, fluzoparib showed good pharmacokinetic properties, favorable toxicity profile, and superior antitumor activity in HR‐deficient xenografts models. Furthermore, fluzoparib in combination with apatinib or with apatinib plus paclitaxel elicited significantly improved antitumor responses without extra toxicity. Based on these findings, studies to evaluate the efficacy and safety of fluzoparib (phase II) and those two combinations (phase I) have been initiated. Taken together, our results implicate fluzoparib as a novel attractive PARP inhibitor.

6 February 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
FLFei Long
Fei Long
YHYe He
Ye He
HFHaoyu Fu
Haoyu Fu
YLYun Li
Yun Li
XBXubin Bao
Xubin Bao
LLLiguang Lou
Liguang Lou
Inhibition of the cyclin‐dependent kinase (CDK) 4/6‐retinoblastoma (RB) pathway is an effective therapeutic strategy against cancer. Here, we performed a preclinical investigation of the antitumor activity of SHR6390, a novel CDK4/6 inhibitor. SHR6390 exhibited potent antiproliferative activity against a wide range of human RB‐positive tumor cells in vitro, and exclusively induced G1 arrest as well as cellular senescence, with a concomitant reduction in the levels of Ser780‐phosphorylated RB protein. Compared with the well‐known CDK4/6 inhibitor palbociclib, orally administered SHR6390 led to equivalent or improved tumor efficacy against a panel of carcinoma xenografts, and produced marked tumor regression in some models, in association with sustained target inhibition in tumor tissues. Furthermore, SHR6390 overcame resistance to endocrine therapy and HER2‐targeting antibody in ER‐positive and HER2‐positive breast cancer, respectively. Moreover, SHR6390 combined with endocrine therapy exerted remarkable synergistic antitumor activity in ER‐positive breast cancer. Taken together, our findings indicate that SHR6390 is a novel CDK4/6 inhibitor with favorable pharmaceutical properties for use as an anticancer agent.

23 May 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
HWHongbin Wang
Hongbin Wang
WWWenqian Wang
Wenqian Wang
YXYongping Xu
Yongping Xu
YYYong Yang
Yong Yang
XCXiaoyan Chen
Xiaoyan Chen
LLLiguang Lou
Liguang Lou
Trastuzumab emtansine (T‐ DM 1), an antibody–drug conjugate ( ADC ) consisting of human epidermal growth factor receptor 2 ( HER 2)‐targeted mA b trastuzumab linked to antimicrotubule agent mertansine ( DM 1), has been approved for the treatment of HER 2‐positive metastatic breast cancer. Acquired resistance has been a major obstacle to T‐ DM 1 treatment, and mechanisms remain incompletely understood. In the present study, we established a T‐ DM 1‐resistant N87‐ KR cell line from HER 2‐positive N87 gastric cancer cells to investigate mechanisms of acquired resistance and develop strategies for overcoming it. Although the kinetics of binding, internalization, and externalization of T‐ DM 1 were the same in N87‐ KR cells and N87 cells, N87‐ KR was strongly resistant to T‐ DM 1, but remained sensitive to both trastuzumab and DM 1. T‐ DM 1 failed to inhibit microtubule polymerization in N87‐ KR cells. Consistently, lysine‐ MCC ‐ DM 1, the active T‐ DM 1 metabolite that inhibits microtubule polymerization, accumulated much less in N87‐ KR cells than in N87 cells. Furthermore, lysosome acidification, achieved by vacuolar H + ‐ ATP ase (V‐ ATP ase), was much diminished in N87‐ KR cells. Notably, treatment of sensitive N87 cells with the V‐ ATP ase selective inhibitor bafilomycin A1 induced T‐ DM 1 resistance, suggesting that aberrant V‐ ATP ase activity decreases T‐ DM 1 metabolism, leading to T‐ DM 1 resistance in N87‐ KR cells. Interestingly, HER 2‐targeted ADC s containing a protease‐cleavable linker, such as hertuzumab‐vc‐monomethyl auristatin E, were capable of efficiently overcoming this resistance. Our results show for the first time that a decrease in T‐ DM 1 metabolites induced by aberrant V‐ ATP ase activity contributes to T‐ DM 1 resistance, which could be overcome by HER 2‐targeted ADC s containing different linkers, including a protease‐cleavable linker. Accordingly, we propose that V‐ ATP ase activity in lysosomes is a novel biomarker for predicting T‐ DM 1 resistance.